At #BIO2022, Our CEO Mike Dudley will join AMR Action Fund CEO Henry Skinner and Senior White House Advisor at the White House Office of Science & Technology Policy Matt Hepburn to discuss the challenges in bringing new #antibiotics to patients and tackling #AMR – moderated by Diane Shader Smith. bio.org/events/bio-int…

In comparison to the most clinically relevant beta-lactamase inhibitors, xeruborbactam showed activity against all 10 beta-lactamase enzyme classes studied, which no other BLI included in the Pharmaceuticals MDPI paper achieved. #AMR #IDTwitter bit.ly/3NjLGP1

What's going on with the NDM-9 metallo beta-lactamase? Are there differences in inhibition by new boronate B-inhibitors? Come hear an Emerging Science presentation by Qpex's Olga Lomovskaya on Sat 6/17 @ 2:30pm in Lounge & Learn Area 2. It's Rapid Fire-don't be late! #ASMicrobe

“Qpex is thrilled to become part of Shionogi, a world-class organization with an established legacy and commitment to innovation in the development of products for the treatment of infectious diseases,” said Michael N. Dudley, PharmD, CEO of Qpex. shionogi.com/us/en/news/202…

Thank you David… we agree! davidshlaes.substack.com/p/shionogi-and… SIDP Antimicrobials Working Group IDSA CARB-X Kevin Outterson Pew Research Center Global Antibiotic R&D Partnership (GARDP)

Qpex and Shionogi announce presentations at #IDWeek2023 shionogi.com/global/en/news…

Important milestone in this unique and important collaboration. SIDP IDSA Antimicrobials Working Group CARB-X AMR Action Fund Pew Health Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Timothy Jinks ᐯIᑕTOᖇ ᑎIᘔET

Data on xeruborbactam combinations presented at last year’s IDWeek 2022 are now published. CARB-X AMR Action Fund SIDP Shionogi Inc. (U.S.) IDSA Pew Health Antimicrobials Working Group Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 CDC Antimicrobial Resistance Save Antibiotics Global Antibiotic R&D Partnership (GARDP) The Global Antibiotics Resistance Foundation #AMR

Oral and IV xeruborbactam combinations. It’s early! Thursday 10/12 at 8am ET Room 104.

Qpex is now a Shionogi Group Company. Read what that means about Shionogi Inc. (U.S.) commitment to infectious dieases and #AMR pharmashots.com/16215/nathan-m…

Time is of the essence for patients with infections caused by carbapenem-resistant pathogens. Mortality risk increases with every hour that treatment is delayed. Learn more about Gram-negative bacterial resistance and treatment strategies with Healio: bit.ly/45jSzsj

Our CEO Mike Dudley joined a roundtable of experts to discuss the importance of changes in policy and where he emphasized the importance of application of new improved methods to show value of antibiotics. No Patient Left Behind CARB-X SIDP Global Antibiotic R&D Partnership (GARDP) IDSA Antimicrobials Working Group Shionogi Inc. (U.S.)

Qpex Biopharma scientists will present microbiological data and Phase 1 results for oral xeruborbactam - the first orally bioavailable beta-lactamase inhibitor with inhibitory activity against both serine and metallo beta-lactamases.

“The expertise of Shionogi Inc. (U.S.) & Qpex Biopharma scientists in this facility in the U.S. will enhance drug discovery and development efforts & help make medicines available that can support future public health,economic & nat’l security concerns.”- Phyllis Arthur, Exec VP Biotechnology Innovation Organization

In July's LifeLines Newsletter, discover how Yatiri Bio uses proteomics to revolutionize cancer drug discovery, how the Shionogi lab Qpex Biopharma progresses antimicrobial resistance research, and how our members drive precision medicine forward. Read more: bit.ly/3VWHdYx

Important discussion ahead of UN meetings.

Qpex Biopharma is committed to continuing its position as a leader in innovation and development of therapies in infectious diseases. We are honored to have Michael Dudley presenting at SIDP annual meeting held in conjunction with IDWeek .

Welcome Lynn Connolly, MD, PhD as Chief Medical Officer. With more than 12 years of experience in developing infectious disease treatments, she will lead our clinical development programs and help drive innovation in our expanding drug discovery programs.